|
16. Shevell,M, Schreiber R. Pemoline-associated
hepatic failure: a critical analysis of the literature. Pediatr
Neurol 1997;16:14–6.
17. Silva RR, Munoz DM, Alpert M. Carbamazepine
use in children and adolescents with features of attention-deficit
hyperactivity disorder: a metaanalysis. J Am Acad Child Adolesc
Psychiatry 1996;35:352–8.
18. Spencer T, Biederman J, Wilens T, Harding M,
O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit
hyperactivity disorder across the life. J Am Acad Child Adolesc
Psychiatry 1996;l35:409–32.
19. Stein M, Krasowski M, Leventhal BL, Phillips
W, Bender BG. Behavioral and cognitive effects of methylxanthines.
A metaanalysis of theophylline and caffeine. Arch Pediatr Adolesc
Med 1996;150:284–8.
20. Thurber S, Walker CE. Medication and hyperactivity:
a metaanalysis. J Gen Psychol 1983;108:79–86.
21. Wilens TE, Biederman J, Spencer T J, Prince
J. Pharmacotherapy of adult attention deficit/hyperactivity disorder:
a review. J Clin Psychopharmacol 1995;15:270–9.
22. Brown RT, Wynne ME, Medenis R. Methylphenidate
and cognitive therapy: a comparison of treatment approaches with
hyperactive boys. J Abnorm Child Psychol 1985;13:69–87.
23. Brown R., Borden KA, Wynne ME, Schleser R, Clingerman
SR. (1986). Methylphenidate and cognitive therapy with ADD children:
a methodological reconsideration. J Abnorm Child Psychol 1986;14:481–97.
24. Brown RT, Borden KA, Wynne ME, Spunt AL. Patterns
of compliance in a treatment program for children with attention
deficit disorder. Journal Compliance Health Care 1988;3:23–39.
25. Conrad WG, Dworkin ES, Shai A. Tobiessen JE.
Effects of amphetamine therapy and prescriptive tutoring on the
behavior and achievement of lower class hyperactive children. J
Learn Disabil 1971;4:509–17.
26. Fehlings DL, Roberts W, Humphries T, Dawe G.
Attention deficit hyperactivity disorder: does cognitive behavioral
therapy improve home behavior? J Dev Behav Pediatr 1991;12:223–8.
27. Firestone P, Crowe D, Goodman JT, McGrath P.
Vicissitudes of follow-up studies: differential effects of parent
training and stimulant medication with hyperactives. Am J Orthopsychiatry
1986;56:184–94.
28. Gillberg C, Melander H, von Knorring AL, Janols
LO, Thernlund G, Hagglof B, and others. Long-term stimulant treatment
of children with attention-deficit hyperactivity disorder symptoms.
A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry
1997;54:857–64.
29. Gittelman-Klein R, Klein DF, Katz S, Saraf K,
Pollack E. Comparative effects of methylphenidate and thioridazine
in hyperkinetic children. I. Clinical results. Arch Gen Psychiatry
1976;33:1217–31.
30. Greenhill LL, Rieder RO, Wender PH, Buchsbaum
M, Zhan TP. Lithium carbonate in the treatment of hyperactive children.
Arch Gen Psychiatry 1973;28:636–40.
31. Kupietz SS, Winsberg BG, Richardson E, Maitinsky
S. Effects of methylphenidate dosage in hyperactive reading-disabled
children: I. Behavior and cognitive performance effects. J Am Acad
Child Adolesc Psychiatry 1988;27:70–7.
32. Linden M, Habib T, Radojevic V. A controlled
study of the effects of EEG biofeedback on cognition and behavior
of children with attention deficit disorder and learning disabilities.
Biofeedback Self Regulation 1996;21:35–49.
33. MTA. 14-month randomized clinical trial of treatment
strategies for attention deficit hyperactivity disorder. Arch Gen
Psychiatry 1999;56:1073–86.
34. Quinn PO, and Rapoport JL. One-year follow-up
of hyperactive boys treated with imipramine or methylphenidate.
Am J Psychiatry 1975;132:241–5.
35. Schachar RJ, Tannock R, Cunningham C, Corkum
PV. Behavioral, situational, and temporal effects of treatment of
ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry 1997;36:754–63.
36. Barkley RA, Fischer M, Edelbrock CS, Smallish
L. The adolescent outcome of hyperactive children diagnosed by research
criteria: I. An 8-year prospective follow-up study. J Am Acad Child
Adoles Psychiatry 1990;29:546–57.
37. Berlin JA. Does blinding of readers affect the
results of meta-analyzes? University of Pennsylvania metaanalysis
blinding study group. Lancet 1997;350:185–6.
38. Jadad AR, Moore RA, Carroll D, Jenkinson C,
Reynolds DM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports
of randomized clinical trials: Is blinding necessary? Controlled
Clinical Trials 1996;17:1–12.
39. Moher D, Pham B, Jones A, Cook D, Jadad A, Moher
M, Tugwell P, Klassen T. Does quality of reports of randomized trials
affect estimates of intervention efficacy reported in meta-analyzes?
Lancet 1998;352:609–13.
40. Schulz KF, Chalmers I, Hayes RJ, Altman DG.
Empirical evidence of bias: Dimensions of methodological quality
associated with estimates of treatment effects in controlled trials.
JAMA 1995;273:408–12.
41. Bero LA, Rennie D. Influences on the quality
of published drug trials. International Journal of Technology Assessment
Health Care 1996;12:209–37.
42. Cho MK, Bero LA. The quality of drug studies
published in symposium proceedings. Ann Intern Med 1996;124:485–9.
|
|
43. Taylor E, Schachar R, Thorley G, Weiselberg
HM, Everitt B, Rutter M. Which boys respond to stimulant medication?
A controlled trial of methylphenidate in boys with disruptive behaviours.
Psychol Med 1987;17:121–43.
44. Szatmari P, Offord DR, Siegel LS, Finlayson
MA, Tuff L. The clinical significance of neurocognitive impairments
among children with psychiatric disorders: diagnosis and situational
specificity. J Child Psychol Psychiatry 1990;31:287–99.
45. Richardson E, Kupietz SS, Winsberg BG, Maitinsky
S, Mendell N. Effects of methylphenidate dosage in hyperactive reading-disabled
children: II Reading achievement. J Am Acad Child Adolesc Psychiatry
1988;27:78–87.
46. Safer DJ, Zito JM, Fine EM. Increased methylphenidate
usage for attention deficit disorder in the 1990s. Pediatrics 1996;98:1084–8.
47. Miller A, Lee SK, Raina P, Klassen A, Zupancic
J, Olsen L. A review of therapies for attention-deficit/hyperactivity
disorder. Ottawa: Canadian Coordinating Office for Health Technology
Assessment (CCOHTA) 1998; RFP #ADHD-1196:. http://www.ccohta.ca/main-e.html
48. Safer DJ, Krager JM. A survey of medication
treatment for hyperactive/inattentive students. JAMA 1988;260:2256–8.
49. Swanson JM, Lerner M, Williams L. More frequent
diagnosis of attention deficit-hyperactivity disorder. NEJM 1995;333:944.
50. Oxman AD, Guyatt GH. Validation of an index
of the quality of review articles. J Clin Epidemiol 1991;44:1271–8.
51. Pelham WE Jr, Wheeler T. Empirically supported
psychosocial treatments for attention deficit hyperactivity disorder
[comment] [see comments]. J Clin Child Psychol 1998;27:190–205.
52. Ioannidis JPA, Cappelleri JC, Lau J. Issues
in comparisons between meta- analyses and large trials. JAMA 1998;279:1089–93.
53. Ezzo J, Berman B. Is acupuncture effective for
the treatment of chronic pain? A systematic review. Pain 2000;86:217–25.
54. Kahn KS, Daya S, Jadad AR. The importance of
quality of primary studies in producing unbiased systematic reviews.
Arch Intern Med 1996;156:661–6.
55. Boyle MH, Jadad AR. Lessons from large trials:
the MTA study as a model for evaluating the treatment of childhood
psychiaric disorder. Can J Psychiatry 1999;44:991–8.
56. Cunningham CE. In the wake of the MTA: charting
a new course for the study and treatment of children with attention-deficit
hyperactivity disorder Can J Psychiatry 1999;44:999–1006.
57. Douglas VI, Barr RG, O’Neill ME, Britton
BG. Short term effects of methylphenidate on the cognitive, learning
and academic performance of children with attention deficit disorder
in the laboratory and the classroom. J Child Psychol Psychiatry
1986;27:191–211.
58. Rapport MD, Stoner G, DuPaul GJ, Birmingham
BK, Tucker S. Methylphenidate in hyperactive children: Differential
effects of dose and mastery level on children’s learning performance.
J Abnorm Child Psychol 1985;13:227–44.
59. Tannock R, Schachar RJ, Carr RP, Logan GD. Dose-response
effects of methylphenidate on academic performance and overt behavior
in hyperactive children. Pediatrics 1989;84:648–57.
60. Silverman WA, Altman DG. Patients’ preferences
and randomized trials. Lancet 1996;347:171–4.
----------------------------------------------
Manuscript received and accepted October 2002.
1 Staff Psychiatrist and Senior Scientist, Department of
Psychiatry, University of Toronto, Division of Child and Adolescent
Psychiatry; Brain and Behaviour Program, Research Institute, The
Hospital for Sick Children, Toronto, Ontario.
2 Director, McMaster University Evidence-based Practice
Centre, Health Information Research Unit, Hamilton, Ontario. .
3 Research Assistant, Department of Clinical Epidemiology
and Biostatistics, McMaster University, Hamilton, Ontario.
4 Senior Scientist, Department of Psychiatry and Behavioural
Neurosciences, McMaster University, Hamilton, Ontario.
5 Research Assistant, McMaster University Evidence-based
Practice Centre, Health Information Research Unit, Hamilton, Ontario;
Planning and Administration, Cancer Care Ontario.
6 Department of Pediatrics, McMaster University, Hamilton
Health Sciences Corporation, Hamilton, Ontario.
7 Clinical Psychologist, Children’s Hospital, Hamilton
Health Sciences, Hamilton, Ontario.
Address for correspondence:
Dr R Schachar, Division of Child and Adolescent Psychiatry, The
Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G
1X8
e-mail:russell.schachar@sickkids.on.ca
|
